Startup harnesses data from consumer wearables to predict the onset of inflammation surges linked to chronic diseases.
Canadian-Israeli healthtech startup Sensifai Health has emerged from stealth with an AI-powered preventive medicine platform that detects systemic inflammation before symptoms appear. The Montreal-based company claims it has developed the first “clinically validated” technology capable of identifying early immune signals using only data from consumer wearable health-tracking devices, with no needles or additional hardware required.
Trained on two billion data points and achieving high levels of accuracy in predicting inflammation spikes, Sensifai’s AI system uses data from everyday wearables like smartwatches and other health trackers to detect otherwise invisible immune activity. The company revealed its technology has been validated in a peer-reviewed study published in The Lancet Digital Health, where it demonstrated 90% sensitivity in predicting inflammation surges in healthy patients exposed to a live attenuated flu vaccine.
Originating from research conducted at the McGill University Health Centre, the Sensifai platform continuously analyzes passive physiological data, generating personalized composite inflammation scores that can be used to alert both individuals and clinicians. The system is designed to enable early interventions that could prevent critical health events and significantly reduce hospitalizations.
Sensifai’s initial focus is on chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide. The company claims its technology has demonstrated the potential to prevent up to half of hospitalizations associated with the condition by identifying flare-ups before clinical symptoms emerge.
Designed for applications in both clinical care and consumer wellness, Sensifai’s device-agnostic technology supports integration with existing healthcare infrastructure, digital health platforms, pharmaceutical development and wearable ecosystems. Ultimately, the company aims to help support the shift from reactive to proactive healthcare, claiming its platform’s potential extends far beyond COPD into a wide range of chronic disease areas where pre-symptomatic intervention is crucial.
By targeting the invisible phase of disease progression – where intervention is most effective – Sensifai aims to improve outcomes for patients while delivering measurable cost savings for healthcare systems.
“We’re monetizing the ‘dark matter’ of healthcare, that invisible window where timely interventions can prevent billions in downstream costs, and we’re doing it early, at home,” said Sensifai co-founder and CEO Amir Hadid. “This isn’t AI for AI’s sake; it’s ROI you can measure in empty hospital beds.”
The startup is collaborating with Altesa Biosciences to explore how early immune detection can inform the timely use of antiviral therapies.
“Sensifai’s platform will empower patients with a simple tool that promises to improve their quality of life and health outcomes,” said Altesa CEO Dr Brett Giroir, formerly US Assistant Secretary for Health. “For payers and patients, this platform could be game changing.”
Sensifai also revealed it has secured an undisclosed amount of seed funding, led by Glen Ventures alongside the Eurêka investment fund.
“This is not just another AI health company, it’s a platform that redefines when and how we intervene in the course of disease,” said Glen Ventures’ Samuel Ohayon.
